论文部分内容阅读
骨髓间充质干细胞 (mesenchymalstemcells,MSCs)是目前备受关注的一类具有多向分化潜能的组织干细胞 ,体外可以分化为骨、软骨、脂肪等多种细胞。因此 ,MSCs是细胞治疗和基因治疗的种子细胞之一。为了探索MSCs的迁移和分化趋势 ,为帕金森病 (Parkinsondisease,PD)的干细胞治疗提供理论和实验依据 ,本实验将体外扩增并转染增强型绿色荧光蛋白 (enhancedgreenfluorescentprotein ,EGFP)的人骨髓MSCs注入PD大鼠脑内纹状体 ,观察了人骨髓MSCs在大鼠脑内的存活、迁移、分化以及注射MSCs前后大鼠的行为变化。结果表明 ,人骨髓MSCs在大鼠脑内可存活较长时间 ( 10周以上 ) ;随着时间的延长 ,MSCs迁移范围扩大 ,分布于纹状体、胼胝体、皮质以及脑内血管壁 ;免疫组化法检测证实MSCs在大鼠脑内表达人神经丝蛋白 (neurofilament,NF)、神经元特异性烯醇化酶 (neuron specificeno lase,NSE)以及胶质原纤维酸性蛋白 ( glialfibrillaryacidprotein ,GFAP) ;PD大鼠的异常行为有所缓解 ,转圈数由 8 86±2 0 9r/min下降到 4 87± 2 0 6r/min ,统计学分析P <0 0 5为差异显著。以上观察结果表明 ,骨髓MSCs有望成为治疗PD的种子细胞
Bone marrow mesenchymal stem cells (MSCs) are a group of tissue stem cells with multidirectional differentiation potential, which can be differentiated into many kinds of cells such as bone, cartilage and fat in vitro. Therefore, MSCs are one of the seed cells for cell therapy and gene therapy. In order to explore the migration and differentiation trend of MSCs, we provide theoretical and experimental evidences for the stem cell therapy of Parkinson’s disease (PD). In this study, human bone marrow MSCs were amplified and transfected with enhanced green fluorescent protein (EGFP) The striatum was injected into the brain of PD rats to observe the changes of the survival, migration and differentiation of human bone marrow MSCs in rat brain and the behavioral changes before and after MSCs injection. The results showed that human bone marrow MSCs could survive for more than 10 weeks in rat brain. With the extension of time, the migration of MSCs expanded and distributed in striatum, corpus callosum, cortex and intracerebral wall. Immunohistochemistry The chemotaxis assay confirmed that MSCs expressed human neurofilament (NF), neuron specific enolase (NSE) and glial fibrillary acidic protein (GFAP) in rat brain. PD Abnormal behavior of rats was alleviated, and the number of rotations decreased from 8 86 ± 2 0 9r / min to 4 87 ± 2 0 6r / min. The statistical analysis of P 0 05 showed significant difference. The above observations show that bone marrow MSCs is expected to become a seed cell for the treatment of PD